

Gioacchino Angarano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8716418/publications.pdf>

Version: 2024-02-01

112
papers

3,624
citations

147726

31
h-index

143943

57
g-index

112
all docs

112
docs citations

112
times ranked

4365
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging issue of fluconazole-resistant candidemia in a tertiary care hospital of southern italy: time for antifungal stewardship program. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101206.	0.7	4
2	Lost to follow-up: a challenge over 10 years. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1621-1626.	0.6	2
3	Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. <i>Clinical Drug Investigation</i> , 2021, 41, 437-448.	1.1	19
4	Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab187.	0.4	10
5	Gaining Back What Is Lost: Recovering the Sense of Smell in Mild to Moderate Patients After COVID-19. <i>Chemical Senses</i> , 2020, 45, 875-881.	1.1	52
6	Influence of HIV-1 V2 sequence variability on bacterial translocation in antiretroviral naïve HIV-1 infected patients. <i>Journal of Medical Virology</i> , 2020, 92, 3271-3278.	2.5	0
7	Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. <i>BMC Infectious Diseases</i> , 2020, 20, 196.	1.3	9
8	Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1580-1587.	1.3	10
9	Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. <i>Journal of the Neurological Sciences</i> , 2020, 416, 117011.	0.3	36
10	COVID-19 infection in Crohn's disease under treatment with adalimumab. <i>Gut</i> , 2020, 69, 1364-1365.	6.1	46
11	<i>Sphingomonas paucimobilis</i> outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection. <i>American Journal of Infection Control</i> , 2020, 48, 1267-1269.	1.1	14
12	Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 817-842.	1.0	15
13	Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates. <i>Virology</i> , 2019, 535, 266-271.	1.1	1
14	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. <i>Frontiers in Microbiology</i> , 2019, 10, 769.	1.5	6
15	HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio. <i>PLoS ONE</i> , 2019, 14, e0212882.	1.1	0
16	Influence of HLA-B*18 on liver fibrosis progression in a cohort of HIV/HCV coinfecting individuals. <i>Journal of Medical Virology</i> , 2019, 91, 751-757.	2.5	2
17	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. <i>New Microbiologica</i> , 2018, 41, 112-117.	0.1	3
18	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. <i>Digestive and Liver Disease</i> , 2017, 49, 530-534.	0.4	6
20	Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 296-301.	1.1	8
21	Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort. <i>Atherosclerosis</i> , 2017, 263, 398-404.	0.4	25
22	The elderly and direct antiviral agents: Constraint or challenge?. <i>Digestive and Liver Disease</i> , 2017, 49, 1036-1042.	0.4	8
23	Prevalence of Urinary Schistosomiasis in Migrants in Apulia, a Region of Southern Italy, in the Years 2006–2016. <i>BioMed Research International</i> , 2017, 2017, 1-6.	0.9	2
24	Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. <i>In Vivo</i> , 2017, 31, 125-132.	0.6	13
25	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 263-271.	0.9	39
26	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179.	1.0	60
27	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1150-1154.	1.3	42
28	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	0.9	55
29	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	1.5	58
30	Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection. <i>In Vivo</i> , 2015, 29, 771-5.	0.6	2
31	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	1.1	3
32	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. <i>PLoS ONE</i> , 2014, 9, e94768.	1.1	50
33	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19825.	1.2	5
34	Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men. <i>Infection, Genetics and Evolution</i> , 2014, 23, 176-181.	1.0	29
35	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. <i>Hepatology</i> , 2014, 59, 2101-2109.	3.6	38
36	Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1178-1184.	0.5	28

#	ARTICLE	IF	CITATIONS
37	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	0.9	48
38	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV+HIV Coinfection in Interferon-Naive Patients. <i>Antiviral Therapy</i> , 2014, 19, 735-745.	0.6	5
39	X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process. <i>BMC Infectious Diseases</i> , 2013, 13, 220.	1.3	15
40	Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsychotic drugs. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 191-194.	1.1	7
41	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 339-345.	0.9	14
42	Early Markers of Tubular Dysfunction in Antiretroviral-Experienced HIV-Infected Patients Treated with Tenofovir Versus Abacavir. <i>AIDS Patient Care and STDs</i> , 2012, 26, 5-11.	1.1	24
43	Improved Virological Outcome in Non-B Patients: A Possible Role for Baseline Coreceptor Tropism. <i>Clinical Infectious Diseases</i> , 2012, 55, 165-167.	2.9	3
44	Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009. <i>Journal of Chemotherapy</i> , 2012, 24, 113-121.	0.7	6
45	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	1.8	29
46	An outbreak of HIV-1 BC recombinants in Southern Italy. <i>Journal of Clinical Virology</i> , 2012, 55, 370-373.	1.6	19
47	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	2.0	24
48	Limiting Severe Outcomes and Impact on Intensive Care Units of Moderate-Intermediate 2009 Pandemic Influenza: Role of Infectious Diseases Units. <i>PLoS ONE</i> , 2012, 7, e42940.	1.1	3
49	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
50	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 1164-1173.	2.9	70
51	A Greater Prevalence of X4 Viruses in HIV Type 1 Intravenous Drug Users Reflects a "CD4 ⁺ Effect". <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1029-1031.	0.5	6
52	Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 896-900.	1.3	27
53	Impact of Mutations Outside the V3 Region on Coreceptor Tropism Phenotypically Assessed in Patients Infected with HIV-1 Subtype B. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5078-5084.	1.4	32
54	Are the Proposed env Mutations Actually Associated With Resistance to Maraviroc?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 550-552.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	1.1	94
56	V3 Sequences and Paired HIV Isolates from 52 Non-Subtype B HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 365-372.	0.5	3
57	Both a Protective and a Deleterious Role for the L76V Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1724-1725.	1.4	5
58	Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. <i>Antiviral Research</i> , 2009, 83, 118-126.	1.9	6
59	Co-receptor switch during HAART is independent of virological success. <i>Journal of Medical Virology</i> , 2009, 81, 2036-2044.	2.5	35
60	Prevalence of <i>Plasmodium</i> spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. <i>Malaria Journal</i> , 2009, 8, 12.	0.8	41
61	Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2009, 3, 9132.	0.4	4
62	HIV-1 nonsubtype B distribution across certain resource-rich countries. <i>HIV Therapy</i> , 2009, 3, 467-483.	0.6	1
63	Community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 261-273.	1.2	20
64	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. <i>Current HIV Research</i> , 2009, 7, 425-433.	0.2	1
65	Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. <i>Journal of Medical Virology</i> , 2008, 80, 1695-1706.	2.5	16
66	Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 623-630.	0.5	27
67	Epidemiological Multicentric Italian Society of Infectious and Tropical Diseases Study on Prevalence of Tropical Diseases in Hospitalized Immigrants in Italy During 2002. <i>Infectious Diseases in Clinical Practice</i> , 2008, 16, 105-108.	0.1	0
68	Difficulties in Classifying A/G Recombinants: Methodological Problems or Genetic Variability?. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 840-846.	0.5	3
69	A Multidrug-Resistant (MDR) HIV Type 1 Infection in a Homosexual Man and Identified Source Patient. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1293-1295.	0.5	2
70	Prolonged Lamivudine Treatment in Patients with Chronic Active Anti-HBe-Positive Hepatitis. <i>American Journal of Therapeutics</i> , 2006, 13, 218-222.	0.5	4
71	The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 352-360.	0.9	90
72	HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. <i>Journal of Medical Virology</i> , 2005, 75, 483-490.	2.5	46

#	ARTICLE	IF	CITATIONS
73	HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. <i>Journal of Medical Virology</i> , 2005, 77, 457-459.	2.5	7
74	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	1.9	385
75	HIV-1 Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic-Phenotypic Correlations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 1104-1107.	0.9	4
76	High seroprevalence of human herpesvirus 8 (HHV-8) in HIV-1-infected pregnant women of Southeastern Italy: Association with injection drug use and hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2004, 72, 656-660.	2.5	14
77	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 29-33.	2.5	6
78	Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1587-1598.	0.9	18
79	Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. <i>Journal of Medical Virology</i> , 2003, 70, 1-9.	2.5	16
80	Gender Differences in Antiretroviral Drug-Related Adipose Tissue Alterations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 58-61.	0.9	111
81	HIV-1 Phenotypic Susceptibility to Lopinavir (LPV) and Genotypic Analysis in LPV/r-Naive Subjects With Prior Protease Inhibitor Experience. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 439-447.	0.9	19
82	Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 268-280.	0.9	60
83	Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. <i>Aids</i> , 2003, 17, 2169-2176.	1.0	93
84	Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode?. <i>Aids</i> , 2002, 16, 947-948.	1.0	10
85	Intracellular and cell-free (infectious) HIV-1 in rectal mucosa. <i>Journal of Medical Virology</i> , 2001, 65, 637-643.	2.5	29
86	Opportunistic Parasitic Infections of the Intestinal Tract in the Era of Highly Active Antiretroviral Therapy: Is the CD4+Count So Important?. <i>Clinical Infectious Diseases</i> , 2001, 33, 1609-1611.	2.9	23
87	Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug-Naive Patients Treated with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2001, 184, 983-991.	1.9	104
88	Intrafamilial Transmission of Human Herpesvirus 8. <i>Journal of the National Cancer Institute</i> , 2001, 93, 154-156.	3.0	17
89	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2001, 6, 195-198.	0.6	5
90	Gastrointestinal infection due to <i>Anisakis simplex</i> in southern Italy. <i>European Journal of Epidemiology</i> , 2000, 16, 75-78.	2.5	45

#	ARTICLE	IF	CITATIONS
91	Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. <i>Aids</i> , 2000, 14, F123-F128.	1.0	195
92	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. <i>Aids</i> , 2000, 14, 499-507.	1.0	483
93	Disseminated <i>Mycobacterium terrae</i> Infection in a Patient with Advanced Human Immunodeficiency Virus Disease. <i>Clinical Infectious Diseases</i> , 2000, 30, 831-835.	2.9	23
94	Immunological markers in HIV-infected pregnant and non-pregnant women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 90, 37-41.	0.5	5
95	Highly Active Antiretroviral Therapy Failure and Protease and Reverse Transcriptase Human Immunodeficiency Virus Type 1 Gene Mutations. <i>Journal of Infectious Diseases</i> , 1999, 180, 568-571.	1.9	10
96	Detection of Human Herpesvirus 8 in Cervicovaginal Secretions and Seroprevalence in Human Immunodeficiency Virus Type 1 Seropositive and Seronegative Women. <i>Journal of Infectious Diseases</i> , 1999, 179, 1534-1537.	1.9	56
97	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 1018-1024.	1.9	66
98	Efficacy of protease inhibitor-based anti-retroviral therapy in severe HIV-associated thrombocytopenia unresponsive to AZT. <i>British Journal of Haematology</i> , 1999, 105, 1147-1149.	1.2	2
99	Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women largely treated with antiretroviral agents. <i>Aids</i> , 1999, 13, 992.	1.0	8
100	HIV-1 disease progression in women: role of the viral phenotype of the HIV-positive steady partner. <i>Aids</i> , 1999, 13, 1801.	1.0	8
101	Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. <i>Aids</i> , 1998, 12, 737-743.	1.0	53
102	Biological correlates of HIV-1 heterosexual transmission. <i>Aids</i> , 1997, 11, 1089-1094.	1.0	38
103	Familial clustering of HBV pre-C and pre-S mutants. <i>Journal of Hepatology</i> , 1997, 26, 221-227.	1.8	19
104	Giardiasis in HIV: a possible role in patients with severe immune deficiency. <i>European Journal of Epidemiology</i> , 1997, 13, 485-487.	2.5	21
105	The Role of HIV Type 1 Phenotype and Genotype in Long-Term Responders to Zidovudine Therapy. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 969-975.	0.5	3
106	Drug Injection in Jugular Veins: A New Risk Factor for Vascular Diseases in HIV-Infected Patients?. <i>Angiology</i> , 1995, 46, 1049-1052.	0.8	5
107	The Biological Phenotype of HIV-1 Is Usually Retained during and after Sexual Transmission. <i>Virology</i> , 1994, 204, 297-303.	1.1	78
108	Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission. <i>Aids</i> , 1993, 7, 29-32.	1.0	10

#	ARTICLE	IF	CITATIONS
109	HIV-1 variability and progression to AIDS: A longitudinal study. Journal of Medical Virology, 1990, 32, 252-256.	2.5	26
110	NON-A, NON-B HEPATITIS VIRUS. Lancet, The, 1985, 325, 169-171.	6.3	0
111	RAPID SPREAD OF HTLV-III INFECTION AMONG DRUG ADDICTS IN ITALY. Lancet, The, 1985, 326, 1302.	6.3	70
112	Circulating immune complexes in HBsAg-positive and HBsAg-negative chronic liver diseases. Research in Clinic and Laboratory, 1984, 14, 29-35.	0.3	1